ReviewNutrition & metabolism2026
Paeoniflorin: a natural candidate for the treatment of metabolic diseases.
Review in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The global prevalence of metabolic diseases (MetDs) is rising annually and poses a major challenge to public health. Paeoniflorin(PF), a naturally occurring phytochemical, considerably improves insulin sensitivity, glucose and lipid metabolism, bile acid metabolism, inflammation and oxidative stress. This article comprehensively reviews recent research on the role of PF in the treatment of six common MetDs: diabetes mellitus and its complications, non-alcoholic fatty liver, non-alcoholic steatohepatitis, atherosclerosis, cholestasis, and polycystic ovary syndrome, along with its potential molecular mechanisms. In addition, we summarize the pharmacological and toxicological properties of PF and propose strategies to enhance its bioavailability, opening new avenues for its clinical application. Overall, this study demonstrates that PF exhibits therapeutic potential against various MetDs and may serve as a promising candidate for the treatment of metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.